Show simple item record

dc.contributor.authorGarcía García, Gracia
dc.contributor.authorFernández Álvarez, Fátima 
dc.contributor.authorCabeza Montilla, Laura 
dc.contributor.authorDelgado Mora, Ángel Vicente 
dc.contributor.authorMelguizo Alonso, Consolación 
dc.contributor.authorPrados Salazar, José Carlos 
dc.contributor.authorArias Mediano, José Luis 
dc.date.accessioned2021-02-11T08:56:37Z
dc.date.available2021-02-11T08:56:37Z
dc.date.issued2020-11-25
dc.identifier.citationGarcía-García, G., Fernández-Álvarez, F., Cabeza, L., Delgado, Á. V., Melguizo, C., Prados, J. C., & Arias, J. L. (2020). Gemcitabine-Loaded Magnetically Responsive Poly (ε-caprolactone) Nanoparticles against Breast Cancer. Polymers, 12(12), 2790. [doi:10.3390/polym12122790]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/66457
dc.description.abstractA reproducible and efficient interfacial polymer disposition method has been used to formulatemagnetite/poly("-caprolactone) (core/shell) nanoparticles (average size 125 nm, production performance 90%). To demonstrate that the iron oxide nuclei were satisfactorily embedded within the polymeric solid matrix, a complete analysis of these nanocomposites by, e.g., electron microscopy visualizations, energy dispersive X-ray spectroscopy, Fourier-transform infrared spectroscopy, electrophoresis, and contact angle goniometry was conducted. The magnetic responsive behaviour of these nanoparticles was quantitatively characterized by the hysteresis cycle and qualitatively investigated by visualization of the colloid under exposure to a 0.4 T magnet. Gemcitabine entrapment into the polymeric shell reported adequate drug loading values ( 11%), and a biphasic and pH-responsive drug release profile ( four-fold faster Gemcitabine release at pH 5.0 compared to pH 7.4). Cytotoxicity studies in MCF-7 human breast cancer cells proved that the half maximal inhibitory concentration of Gem-loaded nanocomposites was two-fold less than that of the free drug. Therefore, these core/shell nanoparticles could have great possibilities as a magnetically targeted Gemcitabine delivery system for breast cancer treatment.es_ES
dc.description.sponsorshipFEDER, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+i), Instituto de Salud Carlos III (FIS, Spain) PI19/01478es_ES
dc.language.isoenges_ES
dc.publisherMdpies_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectBreast canceres_ES
dc.subjectCore/shelles_ES
dc.subjectDrug loadinges_ES
dc.subjectGemcitabinees_ES
dc.subjectMagnetic drug deliveryes_ES
dc.subjectMagnetitees_ES
dc.subjectpH-responsive drug releasees_ES
dc.subjectPoly("-caprolactone)es_ES
dc.subjectPolymer-coated nanoparticlees_ES
dc.titleGemcitabine-Loaded Magnetically Responsive Poly("-caprolactone) Nanoparticles against Breast Canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/polym12122790
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España